Anika Therapeutics, Inc. (ANIK) Stock Price & Analysis

Anika Therapeutics, Inc. (ANIK) closed at USD 21.42 on Friday, October 23, 2026, up 1.56% on the day. The US market is currently closed; this is not a live price.

The prior close was USD 21.09; the Oct 23, 2026 session ranged USD 20.6–21.45 on volume of 59,202 shares. Market capitalization is $286.66M, with a 52-week range of USD 9.01–22.88 (NMS). Source: Nexqual, retrieved October 24, 2026 at 01:12 UTC.

Also available as compact Markdown for AI agents: nexqual.com/ANIK.md

Key facts (ANIK)

• Last four reported quarters (through Jun 30, 2026): revenue $121M, net income -$3.8M (-3.1% margin), free cash flow $562K (SEC filings).
• Insider open-market purchases, last ~7 months: 3 Form 4 filings, $264K; 0 by opportunistic insiders, 0 by routine insiders.
• Analysts: Buy (mean 1.50 on a 1–5 scale) (2 analysts), mean target USD 23 (range 23–23).
• Total return with dividends: 1Y +110.7% vs S&P 500 +14.0%; 5Y -48.6% vs S&P 500 +76.9%.
• Next earnings: 2026-11-06, EPS estimate USD 0.42, revenue estimate $29.4M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (ANIK)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (ANIK)

P/S 2.4x · P/FCF 510.1x · P/B 2.1x · FCF yield 0.20% · Earnings yield -1.32% · Buyback yield (TTM) 5.25%

Insider purchases (SEC Form 4, open-market, last ~7 months) (ANIK)

3 purchases, $264K. Private placements, offerings, dividend reinvestment and employee stock purchase plan buys are excluded.

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (ANIK)

Consensus Buy (mean 1.50 on a 1–5 scale), 2 analysts; mean target USD 23 (low 23, high 23).

Rating changes, last 120 days:

Total return (dividends reinvested) (ANIK)

ANIK revenue by product line (quarter ended Jun 30, 2026)

ANIK revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

ANIK suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Mar 3, 2026.

ANIK company outlook (results filed Jul 29, 2026)

• “Financial Guidance and Revising 2027 Revenue Forecast BEDFORD, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.”

Quoted word-for-word from the SEC 8-K results press release.

ANIK analyst estimates and revisions

ANIK options: expected move

Options price a move of about ±16.8% (±$3.60) by Dec 18, 2026, which includes earnings on Nov 6, 2026. Over the last 8 reports the stock moved ±16.1% on average.

30-day implied volatility 50.4% vs 31.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 24, 2026 at 01:12 UTC)

Technical Analysis (ANIK)

Nexqual's technical model rates ANIK "BUY" based on 5 bullish and 1 bearish signals across 126 daily candles, as of October 24, 2026 at 01:12 UTC.

Analyst Ratings (ANIK)

Wall Street analysts rate ANIK "Buy" based on 2 analysts, with a mean price target of USD 23 (range USD 23–23), per Nexqual as of October 24, 2026 at 01:12 UTC.

Earnings (ANIK)

Recent Earnings History

Source: Nexqual, October 24, 2026 at 01:12 UTC.

Financials & Fundamentals (ANIK)

Source: Nexqual, October 24, 2026 at 01:12 UTC.

Financial Health Score (ANIK)

Nexqual rates Anika Therapeutics, Inc.'s overall financial health "Mixed" across five dimensions, as of October 24, 2026 at 01:12 UTC.

Ownership (ANIK)

Source: Nexqual, October 24, 2026 at 01:12 UTC.

Leadership (ANIK)

Anika Therapeutics, Inc. is led by Stephen D. Griffin, President, Principal Financial Officer, CEO & Director, per Nexqual as of October 24, 2026 at 01:12 UTC.

Major Backers & Investors (ANIK)

Notable institutional backers of Anika Therapeutics, Inc. include Caligan Partners, LP, Morgan Stanley, Acadian Asset Management. LLC, according to Nexqual as of October 24, 2026 at 01:12 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 24, 2026 at 01:12 UTC.

From Anika Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-03)

Key Strengths & Strategy (as disclosed to the SEC)

• The FDA has broad regulatory compliance and enforcement powers, including issuing Form FDA 483 notices, warning letters, civil money penalties, suspending or delaying clearances or approvals, product recalls, production shutdowns, withdrawal of approvals, product seizures, consent decrees, injunctive relief, or criminal prosecution.
• CE marking involves working with a notified body (or self-certifying for certain low-risk, Class I devices) to demonstrate that the device meets all applicable general safety and performance requirements of EU medical devices legislation, including compliance with the manufacturer's Quality Management System.
• Cingal is our novel, next-generation, non-opioid, single-injection OA Pain Management product, consisting of our proprietary cross-linked HA material combined with a fast-acting steroid, designed to provide both short- and long-term pain relief.
• Here, we have developed significant manufacturing expertise in procedures such as homogenized mixing and filling of highly viscous liquids and creation and manipulation of solid HA into scaffolds or other fiber-based presentations.

Partnerships

• In December 2011, we entered into a fifteen-year licensing agreement with J&J MedTech to exclusively market Monovisc in the United States through December 2026.
• For many years, we have maintained a mutually beneficial commercial partnership with J&J MedTech.

Legal & Regulatory Risks (Item 1A, quoted)

• We are facing a longer than expected pathway to commercialize our Cingal product in the United States, and we may face other unforeseen difficulties in achieving regulatory approval for Cingal and Hyalofast, which could affect our business and financial results.
• We may experience difficulties or delays in securing regulatory approval for Hyalofast, which could negatively affect our business and financial results.
• Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental clearances or approvals for our products may have a material adverse effect on our business, financial condition, and results of operations.
• We cannot be certain that product clearance or approvals, both in the United States and internationally, will not include significant limitations on the product indications, and other claims sought for use, under which the products may be marketed.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 24, 2026 at 01:12 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt